GSK news: Stock dips below MA-20; bullish momentum holds above long-term averages

Traders Union
All News
Financial News
GSK slides 1.48% to GBX 1,793.50

Highlights

GSK expanded its share buyback program, acquiring 248,000 ordinary shares via BNP Paribas SA, raising treasury holdings to about 237 million shares or 5.8% of voting rights.
The company declared a Q3 2025 dividend of 16p per share and maintained its 2025 full-year dividend guidance at 64p per share, affirming stable shareholder returns.
GSK ended its partnership with Ideaya Biosciences, returning two clinical development programs and concluding their 2020 licensing agreement.

Expanded buybacks and partnership exit reinforce stable shareholder stance

GSK expanded its share buyback program, purchasing 248,000 of its own ordinary shares through BNP Paribas SA, increasing treasury holdings to approximately 237 million shares, about 5.8% of voting rights. The company declared a Q3 2025 dividend of 16p per share and maintained its 2025 full-year dividend guidance at 64p per share, confirming commitment to steady shareholder returns. GSK also ended its partnership with Ideaya Biosciences, returning two clinical development programs to Ideaya, concluding the 2020 licensing arrangement.

Diverging momentum signals as support levels align with volatility

The Ichimoku Kijun line at GBX 1,800.25 acts as dynamic support, with the MA-50 providing the next significant support below current levels. Momentum indicators on the daily chart remain moderately positive, as MACD signals a strong buy and ADX indicates a healthy trend, yet oscillators show mixed patterns: RSI and CCI remain in buy territory, Stochastic RSI sits mid-range, and BBP suggests overbought conditions. The price is now near the lower end of today's range after notable intraday volatility following the open, showing divergence between the longer-term bullish trend and short-term selling risk.

High upside probability as range trade persists under bullish bias

In the near term, GSK is expected to fluctuate between GBX 1,790 and GBX 1,835, forming a typical volatility band relative to current levels. There is a very high probability (over 80%) of further price gains, as all key weekly indicators — including RSI, ADX, MACD, and MA-50 — point to continued strength. The baseline scenario favors range-bound trading within this corridor, but a bullish breakout above GBX 1,835 could open the door to further upside, while a drop below GBX 1,790 risks extended declines toward medium-term supports.

Anton Kharitonov, analyst at Traders Union, notes that GSK maintains its broader bullish structure but faces visible short-term selling pressure. He sees the expanded buyback and steady dividend guidance as positive for sentiment, yet cautions that intraday weakness and overbought signals temper upside conviction. Kharitonov remains cautious and highlights the risk of breakdown if GBX 1,790 fails to hold. "My view: until price stabilizes well above GBX 1,835, I remain wary of further volatility and advise defensive positioning."

Previously it was reported that GSK continued to trade above its primary moving averages, reinforcing sustained bullish momentum supported by strong MACD and ADX readings. With a share buyback under way and oscillators diverging near resistance, analysts noted a high probability of further gains as weekly technical indicators remain strongly bullish though caution was advised due to overbought signals.

Source of Data: GSK Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.